August 11, 2022 11:14 AM EDT
News Briefing

Graphite Bio be­gins SCD cell ther­a­py tri­al; Syn­thet­ic Bi­o­log­ic­s' fu­ture rests on VCN ac­qui­si­tion

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Graphite Bio has dosed its first sick­le cell dis­ease pa­tient with its cell ther­a­py, the Bay Area biotech an­nounced this morn­ing.

In its proof-of-con­cept CEDAR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times